Prospective Study FNB, Is It Time To Abandon Cytological Assessment
Public ClinicalTrials.gov record NCT04165018. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Prospective Study FNB, Is It Time To Abandon Cytological Assessment (FACET)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Endoscopic Ultrasound (EUS) is a minimally invasive procedure used by gastroenterologists to examine pancreatic masses and lesions. A fine needle is traversed through an endoscope and used to acquire tissue samples, which are then sent for pathology. The standard approach for diagnosing solid pancreatic lesions has been fine needle aspiration (FNA) (Han et al. 2016). However, the use of FNA comes with its limitations, some of which include multiple needle passes to acquire fluid, the need for on-site cytologists, and decreased diagnostic yield. Fine needle biopsy (FNB) is the latest approach being employed by endosonographers in lieu of FNA. FNB confers several advantages over FNB. First, FNB requires fewer needle passes than FNA to acquire tissue sample for immunohistochemical staining. In addition, FNB provides better tissues samples, greater sensitivity of the tissue core, and thus, improved diagnostic yields (Tian et al. 2018). Finally, FNB is more cost-effective than FNA and relies on pathologists, instead of on-site cytologists, and preserves the tissue core (Tian et al. 2018). The objective of this study is to establish a database of samples placed in formalin for patients who will undergo a fine-needle biopsy (FNB) for pathological evaluation without rapid on site cytological assessment.
Study identification
- NCT ID
- NCT04165018
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 52 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 100 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 8, 2021
- Primary completion
- Apr 5, 2023
- Completion
- Oct 9, 2023
- Last update posted
- Mar 23, 2026
2021 – 2023
United States locations
- U.S. sites
- 2
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Baylor College of Medicine | Houston | Texas | 77030 | — |
| Baylor St. Lukes Medical Center (BSLMC) | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Pancreatic Neoplasms trials
Other public records listing Pancreatic Neoplasms. Sorted by last update posted; newest first. Not a recommendation.
- NCT04137536: A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer Active, not recruiting
- NCT01950572: Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma Recruiting
- NCT05914987: Determining Individualized Cancer Therapy in Pancreatic Cancer Recruiting
- NCT07542041: Artidis Nanomechanical Signature Profiling of Pancreatic Cancer Specimens Recruiting
- NCT05571839: A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors Active, not recruiting
- NCT04406831: The Role of MicroRNA in the Diagnosis, Prognosis and Response to Treatment in Pancreatic Cancer Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04165018, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 23, 2026 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04165018 live on ClinicalTrials.gov.